Evaluation of efficacy in improvement of reflux esophagitis by esomeprazole to the patient treated with conventional PPI.

Evaluation of efficacy in improvement of reflux esophagitis by esomeprazole to the patient treated with conventional PPI. - Evaluation of efficacy in improvement of reflux esophagitis by esomeprazole to the patient treated with conventional PPI.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008179

Enrollment

Registered

2012-06-15

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

reflux esophagitis

Interventions

Esomeprazole

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The patient who has diagnosis of reflux esophagitis by endoscopic examination. 2)The patient treated with PPI more than four weeks. 3)Above 20 years old. 4)Informed consent.

Exclusion criteria

Exclusion criteria: The exclusion criteria. 1)The patient who has a history of allergy to the study drug. 2)Patient who is using atazanavir sulfate. 3)The patient with gastrointestinal diseases such as esophageal stenosis, an irritable bowel syndrome, an inflammatory bowel disease, primary esophagus motor deficit, systemic sclerosis, Zollinger-Ellison syndrome, the malabsorption syndrome and so on. 4)The patient with a gastric ulcer, and/or a duodenal ulcer endoscopically. 5)The patient with severe liver, kidney and heart disease. 6)The patient with a history of the digestive surgical operation or vagotomy. 7)Pregnant or lactation woman. 8)The patient who needs the treatment with the following drugs during the study. Exercise function improvement medicine, gastric mucosa defense factor reinforcement medicine, cholinolytic, antacid, antidepressant, an antianxiety drug, a NSAIDs, low-dose aspirin, bisphosphonate. But the patient uses it before the consent acquisition, and without during changing dosage, a dose during a study time when patient can use it, suppose that combined use is possible. 9)The patient who has to use drug having study drug and interaction. 10)Diazepam, phenytoin, cilostazol, warfarin, a tacrolimus hydrate, digoxin, metildigoxin, itraconazole, a tyrosine kinase inhibior (gefitinib, nilotinib), voriconazole, nelfinavir mesilate, saquinavir mesilate, St. John's wort component food. 11)The patient who was considered ineligible by the investigators.

Design outcomes

Primary

Measure	Time frame
F scale	—

Countries

Japan

Contacts

Public ContactTomiyasu Arisawa

Kanazawa Medical University Department of Gastroenterology

tarisawa@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026